newsfilter
← Latest News
GlobeNewswire·

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and